日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Industries

Total value of medical imports decreases

By Liu Zhihua | China Daily | Updated: 2019-04-16 09:22
Share
Share - WeChat
Bayer Group's booth at the China International Import Expo in Shanghai on Nov 6, 2018. [Photo/China News Service]

Domestic demand remains robust while prices drop due to intensified competition among pharmaceutical firms

The value of medical and healthcare products China imported last year decreased for the first time in "many years" to about $50.43 billion, down by 9.75 percent year-on-year, according to a report released by the China Chamber of Commerce for Import and Export of Medicine and Health Products.

Business insiders said the cause of the decrease is mainly the lower average price of imported medicine due to intensified competition among pharmaceutical companies, rather than changes in import volume.

They also predicted prices are likely to continue to fall in the next few years, while demand will remain robust, and thus the value of medical and healthcare imports will likely be stable or increase slightly in the future.

According to the report released last month, the import volume of medical and healthcare products increased 9.52 percent year-on-year last year, while the average import price dropped by 17.6 percent year-on-year, resulting in a lower total import value.

Among the imports last year, the decrease in value of Western medicine is the main cause of the total import value decline, especially as the import value of Western medicine and biochemical medicine decreased sharply, the report said.

The value of Western medicine, which often takes up the largest value and volume shares among all medical and healthcare products China imports, plunged 24.05 percent year-on-year in 2018 to about $13.03 billion.

The biochemical medicine import value decreased even more sharply to around $4.75 billion, down by 41.21 percent.

"China's demand for imported medical and healthcare products has remained steady in recent years with a tendency toward growth," said Wang Maochun, vice-president of the chamber. "The decline in import value was mainly due to the price drop rather than a volume decrease."

The volume of Western medicine China imported last year increased 1.75 percent year-on-year, while the volume of biochemical medicine dwindled 7.67 percent compared to that in 2017, according to the report.

Wang said the measures the Chinese government has adopted to increase the affordability and accessibility of medicine, such as the pilot drug group-buying program and the generic drug evaluation method, have intensified competition among pharmaceutical companies, which eventually helps cut prices.

In 2018, the prices of 17 titles of anti-cancer drugs were significantly lowered after they made it into the national reimbursement drug list.

The report said the average price of imported Western medicine formulations fell 25.36 percent year-on-year in 2018, and the average price of biochemical medicines slumped 36.32 percent compared to the previous year.

Wang predicted imported medicine prices will likely continue to decline or remain at current levels in the future.

If the multinational pharmaceutical companies, especially overseas firms that produce original drugs, want to maintain their market share in China - the world's second-largest pharmaceutical market after the United States - their medicine prices must remain at a relatively low level, he said.

Shi Lichen, founder of medical consultancy Beijing Dingchen Consultancy, also predicted that imported medicine prices will likely continue dropping "over a long period".

"China has huge market potential for imported medicine, and the demand is growing fast for generic drugs, but pharmaceutical market competition is becoming increasingly fierce," he said.

That is because Chinese pharmaceutical companies have been building up their research and development capacity over the years, and their product competence is growing, and also because China is reviewing and approving drugs faster so there will be more competitors both from China and abroad, he explained.

Shi said competition in the generic drugs segment will be intense, considering the reimbursement provided by medical insurance programs in China for generic drugs is much more generous than in other countries, such as the US.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 精品亚洲国产成av人片传媒 | 国产人妖一区 | 国产在线观 | 国产在线视频网 | 欧美一区二区三区在线观看视频 | 欧美成人伊人久久综合网 | 免费一区| 中文字幕乱码视频32 | 午夜寂寞影视在线观看 | 免费的污污网站 | 亚洲在线观看免费视频 | 最新高清无码专区 | 国产激情在线观看 | 日本一级高清不卡视频在线 | 久久久久无码国产精品一区 | 日韩毛片网站 | jdav视频在线观看免费 | 成人免费网址在线 | 国产精品久久久久久久一区探花 | 欧美成人a∨高清免费观看 久久亚洲欧美日韩精品专区 | a在线视频观看 | 国产欧美日韩亚洲精品区2345 | 国产99精品在线观看 | 色天天爱天天狠天天透 | 成人午夜性视频欧美成人 | 日本视频网站在线观看 | 婷婷国产成人精品视频 | 五月婷婷之综合激情 | 欧美三级视频在线观看 | 久久精品视频在线观看 | 国产欧美日韩不卡一区二区三区 | 国产在线观看一区二区三区 | www.99热这里只有精品 | www操com| 日本理论片好看理论片 | 精品欧美一区二区三区久久久 | 亚州天堂网 | 精品久久一区二区 | 大学生一级毛片全黄毛片黄 | 国产在线毛片 | 欧美黄视频网站 |